Will Serum Institute Join Strides, Gland On The Sputnik V Flight?
Around 550 Million Doses Tied Up So Far
While speculation mounts about Serum Institute being next in line for an RDIF partnership, Gland Pharma and Strides unit Stelis sign up to make COVID-19 vaccine Sputnik V. Part of the 550 million dose output tied up from India so far could be consumed domestically, but exports are a possibility as demand from European countries is set to jump.
You may also be interested in...
Global research consortium to investigate the use of immunoglobulin as a COVID-19 therapy ends following disappointing results from a Phase III trial. Meanwhile, Russian vaccine producer RDIF is snapping up more production capacity in India, where interferon has also progressed as a possible treatment.
Coronavirus Update: Double-Mutant Strain Discovered, India Puts Temporary Hold On AZ Vaccine Exports
Concern in India as a double-mutant strain with E484Q and L452R escape mutations has been found in the state of Maharashtra.
The procurement and authorization of vaccines are under scrutiny in the European Parliament this week. In the meantime, another Sputnik V spat is taking wing between Russia and the EU, while France has resumed the use of AstraZeneca’s vaccine, but only in the over-55s.